Nitetime Cold And Flu label

Nitetime Cold And Flu

Nitetime Cold And Flu Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Liver warning: This product contains acetaminophen. Severe liver damage may occur if you take

  • more than 4 doses ( 8 tablespoons or 120 mL) in 24 hours, which is the maximum daily amount
  • with other drugs containing acetaminophen
  • 3 or more alcoholic drinks every day while using this product

Sore throat warning: If sore throat is severe, persists for more than 2 days, is accompanied or is followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly.

Do not use

  • to make a child sleepy
  • if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.
  • with any other drug containing acetaminophen (prescription or non-prescription). If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist
  • if you are allergic to acetaminophen or any of the inactive ingredients in this product

Ask a doctor before use if you have

  • liver disease
  • glaucoma
  • breathing problems
  • chronic bronchitis
  • a sodium-restricted diet
  • trouble urinating due to an enlarged prostate gland
  • persistent or chronic cough such as occurs with smoking, asthma or emphysema or if cough is accompanied by excessive phlegm (mucus)

Ask a doctor or pharmacist before use if you are taking

  • sedatives or tranquilizers
  • the blood thinning drug warfarin

When using this product

  • do not use more than directed (see overdose warning)
  • excitability may occur, especially in children
  • marked drowsiness may occur
  • avoid alcoholic drinks
  • be careful when driving a motor vehicle or operating machinery
  • alcohol, sedatives and tranquilizers may increase drowsiness

Stop use and ask a doctor if

  • redness or swelling is present
  • new symptoms occur
  • fever gets worse or lasts more than 7 days
  • cough comes back or occurs with rash or headache that lasts.

These could be signs of a serious condition.

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

Overdose warning: Taking more than the recommended dose (overdose) may cause liver damage. In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away. Quick medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms.

Do not use

  • to make a child sleepy
  • if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.
  • with any other drug containing acetaminophen (prescription or non-prescription). If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist
  • if you are allergic to acetaminophen or any of the inactive ingredients in this product

Ask a doctor before use if you have

  • liver disease
  • glaucoma
  • breathing problems
  • chronic bronchitis
  • a sodium-restricted diet
  • trouble urinating due to an enlarged prostate gland
  • persistent or chronic cough such as occurs with smoking, asthma or emphysema or if cough is accompanied by excessive phlegm (mucus)

Ask a doctor or pharmacist before use if you are taking

  • sedatives or tranquilizers
  • the blood thinning drug warfarin

Stop use and ask a doctor if

  • redness or swelling is present
  • new symptoms occur
  • fever gets worse or lasts more than 7 days
  • cough comes back or occurs with rash or headache that lasts.

These could be signs of a serious condition.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

temporarily relieves these common cold/flu symptoms:

  • minor aches and pains
  • headache
  • sore throat
  • fever
  • runny nose and sneezing
  • itchy nose or throat
  • coughs
  • cough due to minor throat and bronchial irritation

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Nitetime Cold And Flu Manufacturers

  • Equate (Walmart Stores, Inc.)
    Nitetime Cold And Flu | Equate (walmart Stores, Inc.)
    No Recall

    Nitetime Cold And Flu | Equate (walmart Stores, Inc.)

    Nitetime Cold And Flu | Equate (walmart Stores, Inc.)
    take only as recommended (see overdose warning) do not exceed 4 doses per 24 hours use dosing cup provided tbsp=tablespoon, mL= milliliter  age dose adults & children 12 yrs and over 2 tablespoons (30 mL) every 6 hours children 4 to 11 yrs do not use unless directed by a doctor children under 4 yrs do not use When using other Day Time or Night Time products, carefully read each label to insure correct dosing
  • Meijer Distribution Inc
    Nitetime Cold And Flu | Meijer Distribution Inc
    No Recall

    Nitetime Cold And Flu | Meijer Distribution Inc

    Nitetime Cold And Flu | Meijer Distribution Inc
    • take only as directed – see Liver warning • do not exceed 8 softgels per 24 hours

    adults & children 12 yrs & over

    2 softgels with water every 6 hrs

    children 4 to under 12 yrs

    ask a doctor

    children under 4 yrs

    do not use

    • when using other Daytime or Nighttime products, carefully read each label to insure correct dosing
  • Nitetime Cold And Flu | Kroger Company
    No Recall

    Nitetime Cold And Flu | Kroger Company

    Nitetime Cold And Flu | Kroger Company
    • take only as directed – see Liver warning • do not exceed 8 softgels per 24 hours

    adults & children 12 yrs & over

    2 softgels with water every 6 hrs

    children 4 to under 12 yrs

    ask a doctor

    children under 4 yrs

    do not use

    • when using other Daytime or Nighttime products, carefully read each label to insure correct dosing
  • Meijer Distribution Inc
    Nitetime Cold And Flu | Meijer Distribution Inc
    No Recall

    Nitetime Cold And Flu | Meijer Distribution Inc

    Nitetime Cold And Flu | Meijer Distribution Inc
    • take only as directed – see Liver warning • do not exceed 8 softgels per 24 hours

    adults & children 12 yrs & over

    2 softgels with water every 6 hrs

    children 4 to under 12 yrs

    ask a doctor

    children under 4 yrs

    do not use

    • when using other Daytime or Nighttime products, carefully read each label to insure correct dosing
  • Meijer Distribution Inc
    Nitetime Cold And Flu | H E B
    No Recall

    Nitetime Cold And Flu | H E B

    Nitetime Cold And Flu | H E B
    • do not use more than directed (see overdose warning) • take every 4 hours, while symptoms persist. Do not take more than 5 packets in 24 hours unless directed by a doctor.

    Age

    Dose

    children under 4 years of age

    do not use

    children 4 to under 12 years of age

    do not use unless directed by a doctor

    adults and children 12 years of age and over

    one packet

    • dissolve contents of one packet into 8 oz. hot water: sip while hot. Consume entire drink within 10-15 minutes. • if using a microwave, add contents of one packet to 8 oz. of cool water: stir briskly before and after heating. Do not overheat.
  • Meijer Distribution Inc
    Nitetime Cold And Flu | Sagent Pharmaceuticals
    No Recall

    Nitetime Cold And Flu | Sagent Pharmaceuticals

    Nitetime Cold And Flu | Sagent Pharmaceuticals
    2.1 Dosage in Adult Patients with Normal Renal Function

    The usual dose of Levofloxacin Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours, as indicated by infection and described in Table 1.

    These recommendations apply to patients with creatinine clearance ≥ 50 mL/min. For patients with creatinine clearance <50 mL/min, adjustments to the dosing regimen are required [see Dosage and Administration (2.3)].

    Table 1: Dosage in Adult Patients with Normal Renal Function (creatinine clearance ≥ 50mL/min)

    1 Due to the designated pathogens [see Indications and Usage (1)].

    2 Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician.

    3 Due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Indications and Usage (1.2)].

    4 Due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Indications and Usage (1.3)].

    5 This regimen is indicated for cUTI due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and AP due to E. coli, including cases with concurrent bacteremia.

    6 This regimen is indicated for cUTI due to Enterococcus faecalis, Enterococcus cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa; and for AP due to E. coli.

    7 Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized B. anthracis. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit [see Clinical Studies (14.9)].

    8 The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients [see Warnings and Precautions (5.10), Use in Specific Populations (8.4), and Clinical Studies (14.9)]. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk.

    9 Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis. Higher doses of levofloxacin typically used for treatment of pneumonia can be used for treatment of plague, if clinically indicated.

    Type of Infection1 Dosed Every 24 hours Duration (days)2 Nosocomial Pneumonia 750 mg 7-14 Community Acquired Pneumonia3 500 mg 7-14 Community Acquired Pneumonia4 750 mg 5 Acute Bacterial Sinusitis 750 mg 5 500 mg 10-14 Acute Bacterial Exacerbation of Chronic Bronchitis 500 mg 7 Complicated Skin and Skin Structure Infections (SSSI) 750 mg 7-14 Uncomplicated SSSI 500 mg 7-10 Chronic Bacterial Prostatitis 500 mg 28 Complicated Urinary Tract Infection (cUTI) or
    Acute Pyelonephritis (AP)5 750 mg 5 Complicated Urinary Tract Infection (cUTI) or
    Acute Pyelonephritis (AP)6 250 mg 10
    Uncomplicated Urinary Tract Infection 250 mg 3 Inhalational Anthrax (Post-Exposure), adult and pediatric patients > 50 kg7,8
    Pediatric patients < 50 kg and ≥ 6 months of age7,8 500 mg
    See Table 2 below (2.2) 608
    608 Plague, adult and pediatric patients > 50 kg9
    Pediatric patients < 50 kg and ≥ 6 months of age 500 mg
    see Table 2 below (2.2) 10 to 14
    10 to 14 2.2 Dosage in Pediatric Patients

    The dosage in pediatric patients ≥ 6 months of age is described below in Table 2.

    Table 2: Dosage in Pediatric Patients ≥ 6 months of age

    1 Due to Bacillus anthracis [see Indications and Usage (1.13)] and Yersinia pestis [see Indications and Usage (1.14)].

    2 Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician.

    3 Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized B. anthracis. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit [see Clinical Studies (14.9)]

    4 The safety of levofloxacin in pediatric patients for durations of therapy beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients [see Warnings and Precautions (5.10), Use in Specific Populations (8.4), and Clinical Studies (14.9)]. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk.

    5 Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis.

    Type of Infection1 Dose Freq. Once
    every Duration2 Inhalational Anthrax (post-exposure)3,4     Pediatric Patients > 50 kg

    500 mg 24hr 60 days4     Pediatric Patients < 50 kg
        and ≥ 6 months of age 8 mg/kg
    (not to exceed
    250 mg per dose) 12hr 60 days4 Plague5
        Pediatric Patients > 50 kg

    500 mg
    24hr 10 to 14 days     Pediatric Patients < 50 kg
        and ≥ 6 months of age 8 mg/kg
    (not to exceed
    250 mg per dose) 12hr 10 to 14 days 2.3 Dosage Adjustment in Adults with Renal Impairment

    Administer levofloxacin with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced.

    No adjustment is necessary for patients with a creatinine clearance ≥ 50 mL/min.

    In patients with impaired renal function (creatinine clearance <50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance [see Use in Specific Populations (8.6)].

    Table 3 shows how to adjust dose based on creatinine clearance.

    Table 3: Dosage Adjustment in Adult Patients with Renal Impairment (creatinine clearance <50 mL/min) Dosage in Normal Renal
    Function Every 24 hours Creatinine Clearance
    20 to 49 mL/min Creatinine Clearance
    10 to 19 mL/min Hemodialysis or Chronic
    Ambulatory Peritoneal
    Dialysis (CAPD) 750 mg 750 mg every 48 hours 750 mg initial dose, then
    500 mg every 48 hours 750 mg initial dose, then
    500 mg every 48 hours 500 mg 500 mg initial dose, then
    250 mg every 24 hours 500 mg initial dose, then
    250 mg every 48 hours 500 mg initial dose, then
    250 mg every 48 hours 250 mg No dosage adjustment
    required 250 mg every 48 hours. If
    treating uncomplicated
    UTI, then no dosage
    adjustment is required No information on dosing
    adjustment is available 2.4 Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins

    Levofloxacin Injection

    Levofloxacin Injection should not be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line [see Dosage and Administration (2.6)].

    2.5 Administration Instructions

    Levofloxacin Injection

    Caution: Rapid or bolus intravenous infusion of levofloxacin has been associated with hypotension and must be avoided. Levofloxacin Injection should be infused intravenously slowly over a period of not less than 60 or 90 minutes, depending on the dosage. Levofloxacin Injection should be administered only by intravenous infusion. It is not for intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.

    Hydration for Patients Receiving Levofloxacin Injection

    Adequate hydration of patients receiving intravenous levofloxacin should be maintained to prevent the formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones [see Adverse Reactions (6.1) and Patient Counseling Information (17.2)].

    2.6 Preparation of Intravenous Product

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

    Because only limited data are available on the compatibility of Levofloxacin Injection with other intravenous substances, additives or other medications should not be added to Levofloxacin Injection Premix in Single-Use Flexible Containers, or infused simultaneously through the same intravenous line. If the same intravenous line is used for sequential infusion of several different drugs, the line should be flushed before and after infusion of Levofloxacin Injection with an infusion solution compatible with Levofloxacin Injection and with any other drug(s) administered via this common line.

    Levofloxacin Injection Premix in Single-Use Flexible Containers (5 mg/mL)

    Levofloxacin Injection is supplied in flexible containers within a foil overwrap. These contain a premixed, ready to use levofloxacin solution in 5% dextrose (D5W) for single-use. The 100 mL premixed flexible containers contain either 250 mg/50 mL or 500 mg/100 mL of levofloxacin solution. The 150 mL flexible container contains 750 mg/150 mL of levofloxacin solution. The concentration of each container is 5 mg/mL. No further dilution of these preparations is necessary. Because the premix flexible containers are for single-use only, any unused portion should be discarded.

    Instructions for the Use of Levofloxacin Injection Premix in Flexible Containers:

    Tear outer wrap at the notch and remove solution container. Check the container for minute leaks by squeezing the inner bag firmly. If leaks are found, or if the seal is not intact, discard the solution, as the sterility may be compromised. Do not use if the solution is cloudy or a precipitate is present. Use sterile equipment. WARNING: Do not use flexible containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete.

    Preparation for Administration:

    Close flow control clamp of administration set. Remove cover from port at bottom of container. Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. NOTE: See full directions on administration set carton. Suspend container from hanger. Squeeze and release drip chamber to establish proper fluid level in chamber during infusion of Levofloxacin Injection Premix in Flexible Containers. Open flow control clamp to expel air from set. Close clamp. Regulate rate of administration with flow control clamp.
  • Meijer Distribution Inc
    Nitetime Cold And Flu | Meijer Distribution Inc
    No Recall

    Nitetime Cold And Flu | Meijer Distribution Inc

    Nitetime Cold And Flu | Meijer Distribution Inc
    • take only as directed – see Liver warning • use dose cup • do not exceed 4 doses per 24 hrs

    adults & children 12 yrs & over

    30 mL (2 TBSP) every 6 hrs

    children 4 to under 12 yrs

    ask a doctor

    children under 4 yrs

    do not use

    • when using other Daytime or Nighttime products, carefully read each label to insure correct dosing
  • Meijer Distribution Inc
    Nitetime Cold And Flu | Meijer Distribution Inc
    No Recall

    Nitetime Cold And Flu | Meijer Distribution Inc

    Nitetime Cold And Flu | Meijer Distribution Inc
    • take only as directed - see Overdose warning • use dose cup • do not exceed 4 doses per 24 hrs

    adults & children 12 yrs & over

    30 mL (2 TBSP) every 6 hrs

    children 4 to under 12 yrs

    ask a doctor

    children under 4 yrs

    do not use